No Data
Express News | InnoCare and KeyMed Jointly Announce the License Agreement With Prolium for Cd20Xcd3 Bispecific Antibody Icp-B02
KEYMED BIO-B (02162.HK) has signed a licensing agreement with Prolium for the development and commercialization of CM355 (ICP-B02).
Gelonghui, January 20th丨KEYMED BIO-B (02162.HK) announced that Chengdu KEYMED BIO-B, Peking INNOCARE, and the joint venture have signed an agreement with Prolium for the development and commercialization of CM355. According to the terms of the agreement, Prolium will have exclusive rights to develop, register, produce, and commercialize CM355 in global non-oncological indications and in regions outside Asia for oncological indications. According to the agreement, the relevant payments will be shared equally by Chengdu KEYMED BIO-B and Peking INNOCARE. CM355 is a CD20×CD3 bispecific antibody that targets CD20 and
Express News | KeyMed Biosciences - License Agreement With Prolium for Development and Commercialization of Cm355
【Brokerage Focus】BOCOM INTL points out that Innovative Drugs companies continue the trend of going abroad, and is bullish on the Sector, which still has significant room for recovery.
Jinwu Finance | BOCOM INTL stated that in the new year, Chinese Innovative Drugs companies continue the trend of going abroad. INNOVENT BIO (01801), SIMCERE PHARMA (02096), Kangnuo Ya (02162), Kelun Botai (06990) / HeBo Pharma (02142), Ying'en Bio and other companies successfully licensed their Innovative Drug Assets through MNC big pharma or through NewCo format. The bank believes that going abroad will remain one of the biggest highlights of the Innovative Drugs Sector in 2025, and more significant Trades are worth looking forward to. In combination with previous drug and medical equipment procurement continuously creating funding space for medical insurance payments of innovative varieties, subsequent finance and medical insurance/business.
Press Release: Timberlyne Therapeutics Launches With a $180 Million Series A Financing to Advance CM313, a Potentially Best-in-Class Anti-CD38 Monoclonal Antibody, for Diseases of High Unmet Medical Needs
Express News | KeyMed Biosciences Inc - Group to Receive Upfront and Near-Term Payment of US$30 Mln & Stake of Timberlyne Therapeutics
No Data
